Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

Overview

Journal Medicina (Kaunas)

Publisher MDPI

Specialty General Medicine

Date 2023 Apr 28

PMID 37109700

Authors

Munteanu Madalina Andreea

Swarnkar Surabhi

Popescu Razvan-Ionut

Ciobotaru Lucia

Nicolae Camelia

Tufanoiu Emil

Nanea Ioan Tiberiu

Affiliations

Soon will be listed here.

Abstract

There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys' sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose reabsorption by SGLT2. Patients with type 2 diabetes mellitus (T2DM) benefit the most from reduced blood glucose levels, although this is just one of the numerous physiological consequences. To establish existing understanding and possible advantages and risks for SGLT2 inhibitors in clinical practice, this article will explore the influence of SGLT2 inhibitors on six major organ systems. In addition, this literature review will discuss the benefits and potential drawbacks of SGLT2 inhibitors on various organ systems and their potential application in therapeutic settings.

Citing Articles

Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.

Rykova E, Klimontov V, Shmakova E, Korbut A, Merkulova T, Kzhyshkowska J Int J Mol Sci. 2025; 26(4).

PMID: 40004134 PMC: 11854991. DOI: 10.3390/ijms26041670.

Renal Abscess Associated with SGLT2 Inhibitors Administration in Heart Failure Without Other Previous Risk Factors: A Case Report.

Munteanu M, Nicolae C, Popescu R, Rusescu A, Paun N, Nanea T Biomedicines. 2025; 13(2).

PMID: 40002802 PMC: 11852447. DOI: 10.3390/biomedicines13020389.

Sodium-Glucose Cotransporter Inhibitors: Cellular Mechanisms Involved in the Lipid Metabolism and the Treatment of Chronic Kidney Disease Associated with Metabolic Syndrome.

Cortes-Camacho F, Zambrano-Vasquez O, Arechaga-Ocampo E, Castaneda-Sanchez J, Gonzaga-Sanchez J, Sanchez-Gloria J Antioxidants (Basel). 2024; 13(7).

PMID: 39061837 PMC: 11274291. DOI: 10.3390/antiox13070768.

Fournier's Gangrene as an Adverse Event Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors.

Suciu I, Grelus A, Cozlac A, Suciu B, Stoica S, Luca S Medicina (Kaunas). 2024; 60(5).

PMID: 38793020 PMC: 11122753. DOI: 10.3390/medicina60050837.

Molecular Background and Clinical Implications of Glucose Disorders in Patients with Psoriatic Arthritis.

Grygiel-Gorniak B, Skoczek W J Clin Med. 2023; 12(18).

PMID: 37762754 PMC: 10532042. DOI: 10.3390/jcm12185814.

References

Scheen A . An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019; 18(4):295-311. DOI: 10.1080/14740338.2019.1602116. View

Abdel-Latif R, Rifaai R, Amin E . Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway. Arch Pharm Res. 2020; 43(5):514-525. DOI: 10.1007/s12272-020-01237-y. View

Jeong H, Park S, Noh Y, Bea S, Filion K, Yu O . Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study. BMC Med. 2023; 21(1):47. PMC: 9913005. DOI: 10.1186/s12916-023-02765-2. View

Dwinata M, Putera D, Hasan I, Raharjo M . SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review. Clin Exp Hepatol. 2021; 6(4):339-346. PMC: 7816633. DOI: 10.5114/ceh.2020.102173. View

Hamed S . Atherosclerosis in epilepsy: its causes and implications. Epilepsy Behav. 2014; 41:290-6. DOI: 10.1016/j.yebeh.2014.07.003. View

Latva-Rasku A, Honka M, Kullberg J, Mononen N, Lehtimaki T, Saltevo J . The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care. 2019; 42(5):931-937. DOI: 10.2337/dc18-1569. View

Saffo S, Taddei T . SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites. Clin Liver Dis (Hoboken). 2019; 11(6):141-144. PMC: 6385962. DOI: 10.1002/cld.714. View

Yaribeygi H, Maleki M, Butler A, Jamialahmadi T, Sahebkar A . Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art. EXCLI J. 2023; 22:53-66. PMC: 9939776. DOI: 10.17179/excli2022-5482. View

McDonagh T, Metra M, Adamo M, Gardner R, Baumbach A, Bohm M . Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With.... Eur Heart J. 2021; 42(48):4901. DOI: 10.1093/eurheartj/ehab670. View

10.

Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle H . Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 1(3):208-19. DOI: 10.1016/S2213-8587(13)70084-6. View

11.

Nguyen T, Wen S, Gong M, Yuan X, Xu D, Wang C . Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice. Diabetes Metab Syndr Obes. 2020; 13:2781-2799. PMC: 7425107. DOI: 10.2147/DMSO.S258593. View

12.

Kern M, Kloting N, Mark M, Mayoux E, Klein T, Bluher M . The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016; 65(2):114-23. DOI: 10.1016/j.metabol.2015.10.010. View

13.

Tan H, Acharya S . Perioperative cessation of sodium-glucose cotransporter-2 inhibitors: 72 hours or seven days?. Anaesth Intensive Care. 2018; 46(4):425. View

14.

Solomon S, Rizkala A, Gong J, Wang W, Anand I, Ge J . Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail. 2017; 5(7):471-482. DOI: 10.1016/j.jchf.2017.04.013. View

15.

Irace C, Casciaro F, Scavelli F, Oliverio R, Cutruzzola A, Cortese C . Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. Cardiovasc Diabetol. 2018; 17(1):52. PMC: 5891980. DOI: 10.1186/s12933-018-0695-y. View

16.

Inzucchi S, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S . SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015; 12(2):90-100. PMC: 4361459. DOI: 10.1177/1479164114559852. View

17.

Gastaldelli A, Repetto E, Guja C, Hardy E, Han J, Jabbour S . Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. Diabetes Obes Metab. 2019; 22(3):393-403. PMC: 7064910. DOI: 10.1111/dom.13907. View

18.

Ujjawal A, Schreiber B, Verma A . Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence?. Ther Adv Endocrinol Metab. 2022; 13:20420188221090001. PMC: 9016587. DOI: 10.1177/20420188221090001. View

19.

Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J . Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015; 21(5):512-7. DOI: 10.1038/nm.3828. View

20.

McGill J, Subramanian S . Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. Am J Cardiol. 2019; 124 Suppl 1:S45-S52. DOI: 10.1016/j.amjcard.2019.10.029. View